AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Rab GDP dissociation inhibitor alpha

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P31150

UPID:

GDIA_HUMAN

Alternative names:

Guanosine diphosphate dissociation inhibitor 1; Oligophrenin-2; Protein XAP-4

Alternative UPACC:

P31150; P50394; Q6FG50; Q7Z2G6; Q7Z2G9; Q7Z2H5; Q7Z2I6

Background:

Rab GDP dissociation inhibitor alpha, also known as Guanosine diphosphate dissociation inhibitor 1, Oligophrenin-2, and Protein XAP-4, plays a crucial role in cellular processes by regulating the GDP/GTP exchange reaction of most Rab proteins. It inhibits the dissociation of GDP from them, and the subsequent binding of GTP to them, promoting the dissociation of GDP-bound Rab proteins from the membrane and inhibiting their activation.

Therapeutic significance:

This protein is linked to Intellectual developmental disorder, X-linked 41, a condition characterized by significantly below average intellectual functioning. Understanding the role of Rab GDP dissociation inhibitor alpha could open doors to potential therapeutic strategies for this disorder.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.